Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

MONTREAL, July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ: ASND) ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransCon^TM PTH (palopegteriparatide) in Canada. Financial terms of the agreement are not disclosed.

TransCon^TM PTH is a parathyroid hormone (PTH) replacement therapy designed to treat chronic hypoparathyroidism, a rare condition caused by absent or insufficient levels of PTH. It is approved under the brand name YORVIPATH® in the European Union, European Economic Area, and Great Britain as a PTH replacement therapy for the treatment of adults with chronic hypoparathyroidism¹. TransCon^TM PTH is also in development for the treatment of adults with chronic hypoparathyroidism in the United States, Japan, and other countries.

A leading Canadian Parathyroidologist Dr Aliya Khan noted that TransCon^TM PTH will be the first approved treatment option available to Canadian patients living with chronic hypoparathyroidism.

"Hypoparathyroidism can seriously impact quality of life and has potentially life-threatening consequences," Dr Khan said. "To have an option that is able to treat the underlying cause of the disease, moving beyond standard oral calcium and active vitamin D, is a great step forward."

"This partnership represents Pendopharm's commitment to bringing innovative medicines that address unmet medical needs to Canadian patients," said Jad Isber, VP and GM of Pendopharm. "We look forward to working with Canadian endocrinologists to make TransCon^TM PTH available to all patients who may benefit from it."

Ascendis Pharma Executive Vice President and Chief Commercial Officer Camilla Harder Hartvig said "We are delighted to partner with Pendopharm to bring TransCon^TM PTH to Canada, contributing to our shared goal of making a meaningful difference in the lives of patients living with chronic hypoparathyroidism."

This new partnership aligns with Pharmascience's ambition to establish itself as a leading organization in the life sciences ecosystem.

"We are excited by the addition of TransCon^TM PTH to our portfolio and the life-changing impact it will have on patients. Our wide range of generic and specialty products demonstrates Pharmascience's continued commitment to improve access to medicines and bring new innovation for patients in Canada and globally" stated Martin Arès, Chief Executive Officer of Pharmascience.

© 2024 Pendopharm, division of Pharmascience Inc. All rights reserved.

About Pendopharm

Pendopharm, a division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine and orthopedics, neurology and cardiology. Pendopharm has extensive experience and knowledge to successfully manage its growing product portfolio.

Additional information: www.pendopharm.com

(Feed generated with FetchRSS)